promo_leaderboard Ad
‹ All stocks
DFTX

Definium Therapeutics

DFTX · NASDAQ · Healthcare
$29.59
▼ $0.57 (-1.89%)
$29.59 $29.75 $29.90 $30.06 $29.59 21:32 15:01
Day range
$29.11 – $30.52
Year range
$10.46 – $49.70
Open
$30.05
Previous close
$30.16
Market cap
$4.05B
Volume (24h)
$107.4K
Volume (52w)
$3.18M
Performance
7D
▼ -14.58%
1M
▼ -10.25%
3M
▼ -35.42%
6M
▲ 30.64%
1Y
▲ 160.94%
YTD
▲ 116.94%
3Y
▲ 976.00%
5Y
▼ -6.95%
All-time
▲ 775.44%
Key statistics
P/E ratio
-9.48
EPS (TTM)
$-3.12
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
136.9M
About Definium Therapeutics

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Visit website
Country: United States of America
Related news
More in Healthcare